ESSA Pharma Announces Results from Phase 1 Clinical Trial

ESSA Pharma (TSX:EPI; NASDAQ:EPIX) announced the results from its Phase 1 portion of the clinical trial of EPI-506 for the treatment of metastatic castration-resistant prostate cancer were presented at the European Society for Medical Oncology.
As quoted in the press release:

EPI-506 (ralaniten acetate) is a first generation N-terminal domain inhibitor of the androgen receptor (AR-NTD).
The open-label, single-arm, dose-escalation study evaluated the safety, pharmacokinetics, maximum tolerated dose, and anti-tumor activity of EPI-506 in men with end-stage mCRPC who have progressed after prior enzalutamide and/or abiraterone treatment and may have received one prior line of chemotherapy. Twenty-eight patients were available for analysis and each patient had received four or more prior therapies for prostate cancer at the time of study entry. Patients self-administered oral doses of EPI-506 ranging from 80 mg to 3600 mg, with mean drug exposure of 85 days (range of eight to 535 days).

Click here to read the full press release.

Source: www.newswire.ca